New Mpox Variant Raises Alarm: Experts Warn of Increased Transmissibility Risks!
Health officials are sounding the alarm over a newly identified and highly transmissible mpox variant that is believed to be driving a surge in cases in the Democratic Republic of Congo (DRC). This alarming development highlights the urgent need for public awareness and action regarding this infectious disease.
The newly discovered strain is a descendant of the more lethal Clade 1a variant, which has been detected in the DRC. Experts have raised concerns about this variant due to its significant health implications. Clade 1a, previously known as monkeypox, has an estimated fatality rate of up to 10%, considerably higher than other recent variants. The emergence of this strain is particularly concerning as it carries the APOBEC3 mutation, which is known to enhance its infectious potential.
This mutation has also been observed in the Clade 1b strain, which has spread beyond Africa to various regions, including the UK, Europe, and Asia over the past year. Given this context, health experts are calling for swift international action to contain the potential spread of this new variant.
According to the latest data from the World Health Organization (WHO), the DRC has reported over 2,063 mpox cases in 2025, including four deaths. However, it remains unclear how many of these cases are attributed to the newly mutated Clade 1a strain, as older variants continue to circulate.
“We have seen a new variant of Clade 1a with APOBEC3 that has been detected, and unlike the old 1a variant, this one has got high potential for higher transmissibility,” stated Dr. Ngashi Ngongo, head of the mpox incident management team at the Africa Centres for Disease Control and Prevention (Africa CDC), during a briefing.
The WHO indicates that Clade 1 strains typically cause more severe illness and have higher mortality rates compared to Clade 2. Historically, Clade 1a infections have been linked to zoonotic spillover events, with limited human-to-human transmission occurring mainly in close-contact settings. The fatality rates for Clade 1a range from 1.4% to over 10%, while Clade 2 mortality rates vary between 0.1% and 3.6%. A recent study published in the New England Journal of Medicine estimates Clade 1b’s fatality rate at approximately 3.3%.
Despite the concerns surrounding its transmissibility, there is currently no evidence suggesting that the new Clade 1a strain is associated with increased mortality. “While this variant may spread outside of DRC, the mortality rate seen in Kinshasa, where the new Clade 1a variant co-circulates with Clade 1b, remains less than one percent—much lower than previously thought for Clade 1a,” explained Dr. Lorenzo Subissi, a virologist with the WHO Health Emergencies Programme. He emphasized that mortality rates will largely depend on underlying health conditions, such as malnutrition.
The discovery of this new strain coincides with the WHO’s decision to extend its classification of the ongoing mpox epidemic as a public health emergency of international concern. This designation, first issued last August amid rising Clade 1b cases, remains in effect due to increasing case numbers, geographic spread, ongoing armed conflict in eastern DRC that hampers response efforts, and insufficient funding.
Outbreaks in Africa primarily involve Clade 1a and 1b, with Clade 2 transmission remaining limited. Dr. Ngongo noted that several African countries continue to report rising mpox cases, while escalating violence in the DRC exacerbates the risk of further spread.
Beyond Africa, Clade 1b has been identified in multiple countries, including:
- UK
- US
- Sweden
- Thailand
- India
- Germany
The UK Health Security Agency has reported nine cases, but it maintains that the risk to the UK population remains low.
Since the outbreak began, mpox has caused at least 1,000 deaths in central Africa. The virus typically presents with symptoms such as fever, body aches, fatigue, and distinctive skin lesions. In severe cases, it can spread to the bloodstream, lungs, and other organs, potentially leading to life-threatening complications.
As the situation develops, it is crucial for both healthcare professionals and the public to stay informed about the risks associated with this mpox variant. Awareness and preparedness can play a vital role in controlling its spread and mitigating its impacts on affected communities.
